PCI Biotech Holding ASA

PCI Biotech Holding ASA is a biopharmaceutical clinical stage development company that aims to revolutionize cancer treatment through its innovative photochemical internalization (PCI) technology platform. The company's lead program, fimaVACC, focuses on enhancing immunotherapy in cancer by triggered endosomal release of antigens or nucleic acids encoding antigens. This has shown promising results in Phase I human studies, with a Phase II study in the pipeline to demonstrate enhancement of immunotherapy for the treatment of solid tumors. Additionally, with the fimaNAC program, PCI Biotech is addressing the bottleneck in intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, which holds significant promise. Founded in 2007 and headquartered in Norway, the company has been listed on the Oslo Børs since June 2008.

PCI Biotech Holding ASA's innovative approach and promising results in cancer treatment make it an attractive investment opportunity. The company's focus on leveraging its PCI technology and its successful human trials demonstrate its potential for significant impact in the biopharmaceutical industry. As a venture capital firm, investing in PCI Biotech presents an opportunity to support the development of cutting-edge cancer therapies with the potential for widespread positive outcomes. With a strong foundation and a clear vision for the future, PCI Biotech is well-positioned for growth and success in the biopharmaceutical landscape.